Encephalitis Associated With Immune Checkpoint Inhibitor Treatment in Patients With Melanoma.
Biomarkers, Tumor
Clinical Decision-Making
Disease Management
Disease Susceptibility
Encephalitis
/ diagnosis
Female
Humans
Immune Checkpoint Inhibitors
/ adverse effects
Male
Melanoma
/ complications
Middle Aged
Molecular Targeted Therapy
/ adverse effects
Mutation
Neoplasm Grading
Neoplasm Staging
Treatment Outcome
Journal
Journal of immunotherapy (Hagerstown, Md. : 1997)
ISSN: 1537-4513
Titre abrégé: J Immunother
Pays: United States
ID NLM: 9706083
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
received:
02
11
2020
accepted:
03
03
2021
entrez:
5
5
2021
pubmed:
6
5
2021
medline:
18
1
2022
Statut:
ppublish
Résumé
Since the approval of immune checkpoint anti-programmed cell death protein 1 antibodies (pembrolizumab and nivolumab) and anti-cytotoxic T-lymphocyte-associated protein 4 (ipilimumab) in combination or monotherapy, significant advances have been made in the treatment of metastatic melanoma. The nonspecific immune stimulation resulting from these drugs can case a wide range of side effects in many organs including the nervous system, named immune-related adverse events. Few immune-related encephalitis associated with these antibodies have been described in the literature. It is a rare complication (<1% of the total of immune-related adverse events) but it can be fatal if not diagnosed and treated on time. We describe 3 cases of patients with melanoma, which were treated with a combination of ipilimumab-nivolumab (case 1), ipilimumab monotherapy (case 2), and nivolumab monotherapy (case 3), who developed an encephalitis which was related to immune checkpoint therapy.
Identifiants
pubmed: 33950029
doi: 10.1097/CJI.0000000000000369
pii: 00002371-202106000-00005
doi:
Substances chimiques
Biomarkers, Tumor
0
Immune Checkpoint Inhibitors
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
204-207Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5:95.
Harrison BRA, Tummala S, de Groot J. Neurologic toxicities of cancer immunotherapies: a review. Curr Neurol Neurosci Rep. 2020;20:27.
Williams TJ, Benavides DR, Patrice K-A, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 2016;73:928.
Schneider S, Potthast S, Komminoth P, et al. PD-1 checkpoint inhibitor associated autoimmune encephalitis. Case Rep Oncol. 2017;10:473–478.
Larkin J, Chmielowski B, Lao CD, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017;22:709–718.
Zafar Z, Vogler C, Hudali T, et al. Nivolumab-associated acute demyelinating encephalitis: a case report and literature review. Clin Med Res. 2019;17:29–33.
Quach HT, Robbins CJ, Balko JM, et al. Severe epididymo‐orchitis and encephalitis complicating anti‐PD‐1 therapy. Oncologist. 2019;24:872–876.
Gkoufa A, Gogas H, Diamantopoulos PT, et al. Encephalitis in a patient with melanoma treated with immune checkpoint inhibitors: case presentation and review of the literature. J Immunother. 2020;43:224–229.
Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391–404.
Petersone L, Edner MN, Ovcinnikovs V, et al. T cell/B cell collaboration and autoimmunity: an intimate relationship. Front Immunol. 2018;9:1941.
Johnson DB, Estrada MV, Salgado R, et al. Melanoma-specific MHC-II expression represents a tumour autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582.